CN110129299A - Phospholipase D and its application - Google Patents
Phospholipase D and its application Download PDFInfo
- Publication number
- CN110129299A CN110129299A CN201910528115.0A CN201910528115A CN110129299A CN 110129299 A CN110129299 A CN 110129299A CN 201910528115 A CN201910528115 A CN 201910528115A CN 110129299 A CN110129299 A CN 110129299A
- Authority
- CN
- China
- Prior art keywords
- phospholipase
- ala
- gly
- ser
- asp139ile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6481—Phosphoglycerides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P9/00—Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04004—Phospholipase D (3.1.4.4)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention belongs to the gene engineering technology fields of enzyme, and in particular to a kind of phospholipase D mutant and its preparation and application.Its technical solution is to carry out rite-directed mutagenesis to wild type phospholipase D using recombinant DNA technology, obtain the higher phospholipase D of vigor, then by high vigor phospholipase D in bacillus subtilis expression system, expression in pichia yeast expression system (including Pichia pastoris dissociate expression system and Pichia pastoris surface display system), obtain producing the recombinant bacterial strain of high vigor phospholipase D, after expression, the specific enzyme activity for detecting high vigor phospholipase D improves 38-140% compared with wild type phospholipase D, high vigor phospholipase D is in bacillus subtilis expression system, pichia yeast expression system, fermentation enzyme activity peak is respectively 36.8U/ml in Pichia pastoris surface display system, 48.1U/ml, 140.2U/ (g dry cell weight).
Description
The application is the divisional application of application for a patent for invention 201610402557.7, and 201610402557.7 applying date is
On June 2nd, 2016, application No. is 201610402557.7, a kind of entitled novel phospholipase D and its prepare phosphatidic acid,
The method of phosphatidylserine.
Technical field:
The invention belongs to the gene engineering technology fields of enzyme, and in particular to be obtained by overlapping pcr lactam enzyme by directional anagenesis in vitro
The phospholipase D mutant that specific enzyme activity improves is obtained, and provides and phosphatidic acid and phosphatidylserine is prepared by high vigor phospholipase D catalysis
Method.
Background technique:
Phospholipase D (PLD) is widely distributed, is present in various animals and plants and microorganism.PLD is to the phosphinylidyne in phospholipid molecule
Oxygen key P-O works, and biocatalysis is mainly reflected in two kinds of reactions: (1) the terminal phosphate ester bond on hydrolytic phosphatide is raw
At phosphatidic acid and hydroxy compounds;(2) in the presence of the compound for having another hydroxyl, phosphatidyl can be catalyzed and tied with it
It closes, forms new phosphatide, i.e. phosphatidyl transfer reaction.
Phosphatidic acid (Phosphatidic acid, PA) is a kind of simple and common phosphatide, is widely present in animals and plants
It is the basis of animal and plant cells biomembrane in cell.PA is by glycerol backbone, the fatty acid group of 1 or No. 2 position, No. 3 positions
Phosphate composition.PA is the direct product of PLD effect, and PA is able to drive Ca2+Activation or synergistic activation various enzymes into the cell, with this
Meanwhile PA may additionally facilitate cell mitogen, the formation for promoting intracellular superoxide, the contraction for causing muscle, promote hormone
Secretion induces the effects of platelet aggregation.Based on the above effect, PA can be applicable to the side such as food industry, medical industry, cosmetics
Face.
Phosphatidylserine (phosphatidylserine, PS) is a kind of generally existing phosphatide, is usually located at cell
Film inner layer is the important component of cell membrane, due to participating in a series of film functional responses, especially in the nervous system of human body
In, be one of the important component of brain cell film, to improve memory, relieve stress, repairs brain damage, treat children it is more
The effects of moving disease, depression and prevention senile dementia significant effect.But there is certain purity phosphatidylserine nature
Middle content is rare, therefore prepares with high purity, high-quality phosphatidylserine product and be of great significance.
Enzyme process prepares phosphatidic acid or phosphatidylserine refers under certain condition, is reacted with PLD catalysis substrate (such as PC)
Phosphatidic acid or phosphatidylserine are generated, this method is compared to chemical synthesis with reaction condition is mild, by-product is few, product yield
The advantages that high, high-quality.The difference of production phosphatidic acid or phosphatidylserine is that PLD catalysis reaction type is different, the former
Belong to hydrolysis, the latter is then phosphatidyl transfer (transphosphatidylation) reaction by using PLD, right
The head base of phosphatide is modified.
Enzyme molecule lactam enzyme by directional anagenesis in vitro belongs to the nonideal explosives of protein, belongs to the scope of protein engineering.Usual hand
Section is the diversity for createing molecule in molecular level using molecular biology method, in conjunction with sensitive, high-throughput screening technique,
So as to obtain ideal mutant in a short time.It is not required to understand the space structure of protein in advance, active site, urge
The factors such as change mechanism, but special evolution conditions are artificially created, natural evolution mechanism is simulated, enzyme gene is transformed in vitro,
Obtaining, there are certain expected features to change structure enzyme, unlike this, need to understand in advance the space structure of protein, active site,
The factors such as catalyst mechanism, and shot the arrow at the target according to these factors and to do that be transformed to its DNA is rite-directed mutagenesis.
Rite-directed mutagenesis, also known as design and rational are exactly the insertion, deletion or substitution certain length in known DNA sequence dna
Nucleotide sequence, as it rapidly, the efficient character and characterization for improving destination protein expressed by DNA, be gene studies
A kind of highly useful means in work.Overlapping pcr used in the present invention is one kind of site-directed mutagenesis technique, the technology
Two or more genetic fragments simple, can be carried out quickly to the splicing of outer-gene by termini-complementary, overlap-extension PCR.Weight
Folded round pcr can obtain the product being difficult to by digestion with restriction enzyme, and fast and easy, carry out large fragment
The rite-directed mutagenesis of gene, genetic fragment, which are deleted, and multiple coded sequences are fitting to connection has exclusive advantage.
Bacillus subtilis belongs to gram-positive bacteria.Use of many bacillus subtilises in fermentation industry is existing suitable
Long history, no pathogenicity do not generate any endotoxin, and belong to human enteric bacteria and promote to grow beneficial to anaerobic bacteria, and produce
The organic acids such as lactogenesis acid reduce gut pH, inhibit other pathogenic bacteria to grow indirectly, furthermore it can efficiently be secreted various
Protein, in Microbial Genetics field, bacillus background research it is also fully aware of, codon-bias is unobvious,
Fermentation is simple, growth rapidly, to culture medium without particular/special requirement the advantages that.
Pichia pastoris belongs to unicellular lower eukaryotes, is the more satisfactory tool of expression alien gene.It is in addition to tool
Having prokaryotes to be easy to, culture, breeding is fast, is convenient for except the characteristics such as genetic engineering operation and high density fermentation, also as containing spy
Strong AOX (alcohol oxidase gene) promoter having, can strictly regulate and control the expression of foreign gene with methanol.In addition, training
Support at low cost, product is easily separated.Fermentation medium used is very cheap, and general carbon source is glycerol or glucose and methanol, remaining
For inorganic salts.Foreign protein genes can be carried out stablizing heredity, and as eukaryotic expression system, Pichia pastoris is raw with eukaryon
The subcellular structure of object has the posttranslational modifications machining functions such as glycosylation, fatty acylated, protein phosphorylation.Same saccharomyces cerevisiae
Compared Deng tradition eukaryotic expression system, pichia yeast expression system have become modern molecular biology study most important tool and
Model.In addition, Pichia pastoris surface display system not only has the post translational processing ability of foreign gene and the folding of albumen
The advantages that being superimposed work and appropriateness glycosylation, moreover, the whole-cell catalyst obtained through the system can reuse to reduce
Production cost.
In the present invention, high vigor phospholipase D and its mutant gene are respectively in bacillus subtilis expression system
Expressed in pichia yeast expression system, obtain producing high vigor phospholipase D, after purification with substrate reactions, catalysis prepare phosphatidic acid,
Phosphatidylserine.
Summary of the invention:
The purpose of the present invention is to provide a kind of high vigor phospholipase Ds, and prepare phosphatidic acid and phosphatidyl silk ammonia using it
The method of acid.
To achieve the goals above, one of technical solution provided by the invention are as follows: a kind of phospholipase D mutant, is to be based on
Phospholipase D amino acid sequence shown in SEQ ID No.2, at least one of 139th, 209,256,388,519 therein
Amino acid is replaced into following amino acid: the 139th: Asp139Ile;209th: Asn209Ile;256th:
Asp256Thr;388th: Gln388Cys;519th: Asp519Val;
The gene of the mutant is with 21102 gene of Hao Shi streptomycete (Streptomyces halstedii) TCCC
Group is template, after cloning phospholipase D wild type gene plD (as shown in SEQ ID NO:1), is constructed by digestion, connection etc.
Recombinant vector carries out rite-directed mutagenesis to wild type phospholipase D by overlapping pcr later, obtains mutant gene and (be shown in Table
1)。
To achieve the goals above, the two of technical solution provided by the invention are as follows: rebuild above-mentioned mutant gene
Recombinant vector, and the high efficient expression in bacillus subtilis WB600 and Pichia pastoris GS115 obtain producing high vigor phospholipase D
Recombinant bacterial strain, obtain high vigor phospholipase D by the technologies such as fermenting, extracting.
To achieve the goals above, the three of technical solution provided by the invention are as follows: use high vigor phosphorus prepared by the present invention
Lipase D be catalyzed respectively phosphatidyl choline prepare phosphatidic acid, catalysis phosphatidyl choline and serine prepare phosphatidylserine.
It uses and such as gives a definition in the present invention:
1. the nomenclature of amino acid and DNA nucleic acid sequence
Using the generally acknowledged IUPAC nomenclature of amino acid residue, with three-letter codes form.DNA nucleic acid sequence is using generally acknowledged
IUPAC nomenclature.
2. the mark of phospholipase D mutant
The amino acid being mutated in phospholipase D mutant is indicated using " amino acid of Original amino acid position replacement ".Such as
Asn209Ile indicates that the amino acid of position 209 is substituted for Ile by the Asn of wild type phospholipase D.The number of position corresponds to
The variation of the amino acid sequence number nucleotide of phospholipase D equally uses " original nucleic acid position replacement in SEQ ID NO:2
Nucleotide " indicate, Position Number corresponds to the nucleotides sequence column number of wild type phospholipase D in SEQ ID NO:1.
In the present invention, plD indicates the amino acid sequence of wild type phospholipase D, i.e. original series (such as SEQ ID NO:2
It is shown).Each mutant is indicated with the mode of plDm addend word x, and x is respectively 139,209,256,388,519, wherein 139 generations
The 139th amino acid of table is substituted for Ile by Asp, and 209, which represent the 209th amino acids, is substituted for Ile by Asn, and 256 represent the 256th
Amino acid is substituted for Thr by Asp, and 388, which represent the 388th amino acids, is substituted for Cys by Gln, and 519 represent the 519th amino acids
Val is substituted for by Asp;X is also possible to xm-…-xnForm, indicate the combination mutant in several sites, such as plDm139-209
Indicate that the 139th amino acid is substituted for Ile by Asp, the 209th amino acids are substituted for the mutant of Ile by Asn.Each mutant
Encoding gene is then indicated with the italic of its amino acid representation, if the encoding gene of mutant plDm139 is plDm139.
In the present invention, the combinatorial mutagenesis of amino acid, comprising as follows:
plDm139-209、plDm139-256、plDm139-388、plDm139-519、plDm209-256、plDm209-
388、plDm209-519、plDm256-388、plDm256-519、plDm388-519、plDm139-209-256、plDm139-
209-388、plDm139-209-519、plDm139-256-388、plDm139-256-519、plDm139-388-519、
plDm209-256-388、plDm209-256-519、plDm209-388-519、plDm256-388-519、plDm139-209-
256-388、plDm139-209-256-519、plDm139-209-388-519、plDm139-256-388-519、plDm209-
256-388-519,plDm139-209-256-388-519;
Table 1: sequence control table
The expressive host of the phospholipase D and its mutant is bacillus subtilis WB600, and expression vector is
pBSA43;
The expressive host of the phospholipase D and its mutant is Pichia pastoris GS115, and expression vector is pPIC 9K;
The host cell of the phospholipase D mutant is Pichia pastoris GS115, display carrier pPIC9K-Flo.
Experimental procedure of the invention is specific as follows:
1, a kind of process for constructing high vigor phospholipase D mutant code gene includes the following steps:
(1) the wild type phospholipase D of Hao Shi streptomycete (Streptomyces halstedii) TCCC 21102 will be come from
Gene is connect with carrier pUC-T, construction recombination plasmid pUC-T-plD, passes through over-lap PCR rite-directed mutagenesis wild type phospholipase D base
Cause obtains high vigor phospholipase D mutant code gene;
(2) pUC-T-plDmx containing high vigor phospholipase D mutant code gene is saved.
2, one plant containing high vigor phospholipase D bacillus subtilis recombinant bacterial strain and high vigor phosphatide is prepared with this
The process of enzyme D includes the following steps:
(1) pUC-T-plDmx containing high vigor phospholipase D mutant code gene of preservation is subjected to digestion, will
To high vigor phospholipase D mutant code gene pass through with carrier bacillus coli-bacillus subtilis shuttle plasmid pBSA43
Connection has obtained new recombinant vector;
(2) recombinant vector is transformed into bacillus subtilis WB600, obtains recombinant bacterial strain, later sends out recombinant bacterial strain
Ferment obtains high vigor phospholipase D.
3, one plant containing high vigor phospholipase D Pichia pastoris recombinant bacterial strain and high vigor phospholipase D is prepared with this
Process include the following steps:
(1) pUC-T-plDmx containing high vigor phospholipase D mutant code gene of preservation is subjected to digestion, will
To high vigor phospholipase D mutant code gene and expression vector pPIC 9K by connection obtain new recombinant vector;
(2) recombinant vector is transformed into Pichia pastoris GS115, obtained recombinant bacterial strain is screened by Geneticin and phosphorus
The enzyme activity determination of lipase D obtains the superior strain of high vigor phospholipase D;
(3) it ferments after, prepares high vigor phospholipase D.
4, one plant containing high vigor phospholipase D Pichia pastoris surface display recombinant bacterial strain and high vigor is prepared with this
The process of phospholipase D whole-cell catalyst includes the following steps:
(1) pUC-T-plDmx containing high vigor phospholipase D mutant code gene of preservation is subjected to digestion, will
To high vigor phospholipase D mutant code gene and Pichia pastoris display carrier pPIC9K-Flo by connection obtain new weight
Group carrier;
(2) recombinant vector is transformed into host strain Pichia pastoris GS115, obtains Pichia pastoris surface display phosphorus
Lipase D recombinant bacterial strain.
(3) the high vigor phospholipase D whole-cell catalyst of yeast cell surface display is prepared after recombinant bacterial strain fermenting.
5, the method for phospholipase D of the present invention production phosphatidic acid, phosphatidylserine is utilized.
The utility model has the advantages that
1, the present invention using overlapping pcr to wild type phospholipase D progress rite-directed mutagenesis (plDm139, plDm209,
plDm256、plDm388、plDm519、plDm139-209、plDm139-256、plDm139-388、plDm139-519、
plDm209-256、plDm209-388、plDm209-519、plDm256-388、plDm256-519、plDm388-519、
plDm139-209-256、plDm139-209-388、plDm139-209-519、plDm139-256-388、plDm139-256-
519、plDm139-388-519、plDm209-256-388、plDm209-256-519、plDm209-388-519、plDm256-
388-519、plDm139-209-256-388、plDm139-209-256-519、plDm139-209-388-519、plDm139-
256-388-519, plDm209-256-388-519, plDm139-209-256-388-519), high vigor phospholipase D is obtained,
At 37 DEG C, above-mentioned high vigor phospholipase D at least improves 38.2% than wild type phospholipase D enzyme activity.
2, the present invention has used bacillus subtilis expression system, pichia yeast expression system, Pichia pastoris surface respectively
Display systems, high vigor phospholipase D ferment in each expression system enzyme activity peak be respectively 36.8U/ml, 48.1U/ml,
140.2U/ (g dry cell weight) improves 140% or so compared with wild type.
3, the present invention is respectively 72.4% using the conversion ratio of high vigor phospholipase D production phosphatidic acid and phosphatidylserine
With the utilization of 78.5%, especially yeast display systems, phospholipase D is showed in yeast surface, yeast cells is in production phosphatide
Fixation support is acted as while enzyme again, greatly reduces cost.
Detailed description of the invention:
Fig. 1 is the PCR amplification electropherogram of wild type phospholipase D of the present invention
Wherein: M is DNA Marker, and 1 is phospholipase D;
Fig. 2 is recombinant plasmid pBSA43-plDmx digestion verification figure of the present invention
Wherein: M is DNA Marker, and 1 is pBSA43-plDmx through BamHI and HindIII double digestion;
Fig. 3 is recombinant plasmid pPIC9K-plDmx digestion verification figure of the present invention
Wherein: M is DNA Marker, and 1 is pPIC 9K-plDmx through EcoRI and NotI double digestion;
Fig. 4 is recombinant plasmid pPIC 9K-Flo-plDmx digestion verification figure of the present invention
Wherein: M is DNA Marker, and 1 passes through SnaBI and EcoRI double digestion for pPIC 9K-Flo, and 2 be pPIC 9K-
Flo passes through SnaBI single endonuclease digestion, and 3 pass through SnaBI and EcoRI double digestion for pPIC 9K-Flo-plDmx.
Specific embodiment:
Technology contents of the invention are described further below with reference to embodiment, but the present invention is not limited solely to these implementations
Example cannot be limited the scope of protection of the present invention with following embodiments.
Embodiment 1: the acquisition of wild type phospholipase D
1. wild type phospholipase D comes from Hao Shi streptomycete (Streptomyces halstedii) TCCC 21102,
Extract its genomic DNA.
Wherein the extraction step of Hao Shi streptomyces gene group DNA is as follows:
(1) it is inoculated in 50mL appropriate culture medium from one ring bacterium of picking on the plate of culture thallus, 26 DEG C, 150r/min training
Support 2-3d.
(2) take 1mL culture solution in 1.5mL EP pipe after, 8000r/min is centrifuged 20min, and supernatant, molten with 200 μ L
Liquid I or aqua sterilisa are resuspended.
(3) plus the 50mg/mL lysozyme of 20-50 μ L digests 0.5-1h at 37 DEG C.
(4) the 2%SDS solution of 100 μ L is added, sufficiently reaction to bacteria suspension is presented thick.
(5) isometric Tris balance phenol: chloroform=1:1 is added, is uniformly mixed, 12000rpm is centrifuged 5min, by supernatant
It is transferred in another EP pipe.
(6) it extracts repeatedly twice, it is finally primary with isometric chloroform again up to the appearance of no albumin layer.
(7) isometric isopropanol precipitating DNA, 12000r/min centrifugation 5min is added, discards supernatant, with 500 μ L 75%
Ethanol washing 2 times, 12000r/min is centrifuged 5min after piping and druming every time.
(8) EP pipe is inverted in filter paper or be placed in 55 DEG C of metal baths, with TE buffer or gone out after drying to alcohol-free taste
The dissolution of bacterium water, -20 DEG C of preservations.
2. sequence is as follows by the amplimer of phospholipase D design wild type phospholipase D:
Upstream P1 (SEQ ID NO:5): ATGATCAAGGTTGGTGGTGTTGCTG
Downstream P2 (SEQ ID NO:6): TTAACCCTGACACAAACCTCTAGCGTAATCGT
The reaction system of PCR amplification is 50 μ L, consisting of:
2×LA buffer | 25μL |
dNTPs(2.5mmol/L) | 2μL |
Upstream primer P1 (20 μm of ol/L) | 5μL |
Downstream primer P2 (20 μm of ol/L) | 5μL |
Hao Shi streptomyces gene group DNA | 2μL |
LA Taq archaeal dna polymerase | 0.5μL |
ddH2O | 10.5μL |
Total volume | 50μL |
The setting of amplification program are as follows:
A. initial denaturation: 95 DEG C of 5min;
B. it is denaturalized: 95 DEG C of 30s;
C. it anneals: 70 DEG C 45;
D. extend: 72 DEG C of 90s;
E.b-d reacts 30 circulations;
F. extend: 72 DEG C of 10min.
PCR product is subjected to agarose gel electrophoresis, it can be seen that the band of wild type phospholipase D, total 1683bp
(see Fig. 1), then PCR product is recycled by miniprep dna QIAquick Gel Extraction Kit, obtain wild type phospholipase D, i.e. plD.
Embodiment 2: obtaining high vigor phospholipase D, by taking Asn209Ile single amino acids mutant as an example, final ammonia
Base acid sequence is as shown in table 1.
1. wild type phospholipase D is attached with carrier T.
PlD after purification and pUC-T carrier is attached, and then recombinant plasmid is transferred in bacillus coli DH 5 alpha, is led to
EcoRI, MluI double digestion are crossed, good authentication wild type phospholipase D has been cloned into carrier T.
2. carrying out the rite-directed mutagenesis of single site by overlapping pcr
Rite-directed mutagenesis is carried out based on overlapping pcr, to obtain high vigor phospholipase D, design primer is as follows:
Upstream P1 (SEQ ID NO.5): ATGATCAAGGTTGGTGGTGTTGCTG
Downstream P2 (SEQ ID NO.6): TTAACCCTGACACAAACCTCTAGCGTAATCGT
Overlapping primers P3 (SEQ ID NO.7): ATGGAAGCAACGATCAAAGTGATGTTAGCAGCAGCA
Overlapping primers P4 (SEQ ID NO.8): TGCTGCTGCTAACATCACTTTGATCGTTGCTTCCAT
Overlapping primers P3 and P4 contain the mutation to 209 amino acids residues.
By recombinant plasmid pUC-T-plD, i.e. the recombinant vector that connect with pUC-T carrier of wild type phospholipase D is mould
Plate carries out PCR amplification;
PCR1, reaction system are 50 μ L, consisting of:
2×LA buffer | 25μL |
dNTPs(2.5mmol/L) | 2μL |
Upstream primer P1 (20 μm of ol/L) | 5μL |
Downstream primer P4 (20 μm of ol/L) | 5μL |
Recombinant plasmid pUC-T-plD | 2μL |
LA Taq DNA polymerase | 0.5μL |
ddH2O | 10.5μL |
Total volume | 50μL |
PCR2, reaction system are 50 μ L, consisting of:
2×LA buffer | 25μL |
dNTPs(2.5mmol/L) | 2μL |
Upstream primer P3 (20 μm of ol/L) | 5μL |
Downstream primer P2 (20 μm of ol/L) | 5μL |
Recombinant plasmid pUC-T-plD | 2μL |
LA Taq DNA polymerase | 0.5μL |
ddH2O | 10.5μL |
Total volume | 50μL |
The setting of PCR1 and PCR2 amplification program are as follows:
A. initial denaturation: 95 DEG C of 5min;
B. it is denaturalized: 95 DEG C of 30s;
C. it anneals: 68 DEG C of 30s;
D. extend: 72 DEG C of 45s;
E.b-d reacts 10 circulations;
F. extend: 72 DEG C of 10min.
PCR3, reaction system are as follows:
2×buffer | 25μL |
dNTPs(2.5mmol/L each) | 2μL |
PCR1 product | 1μL |
PCR2 product | 1μL |
LA Taq DNA polymerase | 0.5μL |
ddH2O | 20.5μL |
Total volume | 50μL |
The setting of PCR3 amplification program are as follows:
A. initial denaturation: 95 DEG C of 5min;
B. it is denaturalized: 95 DEG C of 30s;
C. it anneals: 70 DEG C of 45s;
D. extend: 72 DEG C of 90s;
E.b-d reacts 10 circulations;
F. extend: 72 DEG C of 10min.
PCR4, reaction system are as follows:
2×buffer | 25μL |
dNTPs(2.5mmol/L each) | 2μL |
Upstream primer P1 (20 μm of ol/L) | 5μL |
Downstream primer P2 (20 μm of ol/L) | 5μL |
PCR3 product | 2μL |
LA Taq DNA polymerase | 0.5μL |
ddH2O | 10.5μL |
Total volume | 50μL |
The setting of PCR4 amplification program are as follows:
A. initial denaturation: 95 DEG C of 5min;
B. it is denaturalized: 95 DEG C of 30s;
C. it anneals: 70 DEG C of 45s;
D. extend: 72 DEG C of 90s;
E.b-d reacts 30 circulations;
F. extend: 72 DEG C of 10min.
(Beijing Hua Da bio-engineering corporation) is sequenced in finally obtained PCR product, the results showed that, amplification obtains at this time
The phospholipase D segment plDm209 of Asn209Ile.
Embodiment 3: the phospholipase D variant of multiple amino acid mutations is obtained, on the basis of single amino acids mutation with weight
Folded round pcr carries out Asp139Ile, Asp256Thr, Gln388Cys, Asp519Val on the basis of Asn209Ile mutant
For mutation, final amino acid sequence is as shown in SEQ ID NO:4.
Specific strategy is: first realizing double mutation on the basis of single mutation, then carries out third, the 4th and the 5th ammonia
The mutation of base acid.
The mutation of Asp519Val is realized on the basis of Asn209Ile first, step and embodiment 2 are consistent, and design overlapping is drawn
Object, as follows:
Upstream P1 (SEQ ID NO.5): ATGATCAAGGTTGGTGGTGTTGCTG
Downstream P2 (SEQ ID NO.6): TTAACCCTGACACAAACCTCTAGCGTAATCGT
Overlapping primers P5 (SEQ ID NO.9): CAACAACGTAACCGAAGACTTGCAACCAGGATGGG
Overlapping primers P6 (SEQ ID NO.10): CCCATCCTGGTTGCAAGTCTTCGGTTACGTTGTTG
Overlapping primers P5 and P6 contain the mutation to 519 amino acids residues.
By recombinant plasmid pUC-T-plDm209, i.e. the weight that is connect with pUC-T carrier of the gene of encoding mutant body plDm209
Group carrier carries out PCR amplification for template;
PCR1, reaction system are 50 μ L, consisting of:
2×LA buffer | 25μL |
dNTPs(2.5mmol/L) | 2μL |
Upstream primer P1 (20 μm of ol/L) | 5μL |
Downstream primer P6 (20 μm of ol/L) | 5μL |
Recombinant plasmid pUC-T-plDm209 | 2μL |
LA Taq DNA polymerase | 0.5μL |
ddH2O | 10.5μL |
Total volume | 50μL |
PCR2, reaction system are 50 μ L, consisting of:
The setting of PCR1 and PCR2 amplification program are as follows:
A. initial denaturation: 95 DEG C of 5min;
B. it is denaturalized: 95 DEG C of 30s;
C. it anneals: 68 DEG C of 30s;
D. extend: 72 DEG C of 45s;
E.b-d reacts 10 circulations;
F. extend: 72 DEG C of 10min.
PCR3, reaction system are as follows:
2×buffer | 25μL |
dNTPs(2.5mmol/L each) | 2μL |
PCR1 product | 1μL |
PCR2 product | 1μL |
LA Taq DNA polymerase | 0.5μL |
ddH2O | 20.5μL |
Total volume | 50μL |
The setting of PCR3 amplification program are as follows:
A. initial denaturation: 95 DEG C of 5min;
B. it is denaturalized: 95 DEG C of 30s;
C. it anneals: 70 DEG C of 45s;
D. extend: 72 DEG C of 90s;
E.b-d reacts 10 circulations;
F. extend: 72 DEG C of 10min.
PCR4, reaction system are as follows:
The setting of PCR4 amplification program are as follows:
A. initial denaturation: 95 DEG C of 5min;
B. it is denaturalized: 95 DEG C of 30s;
C. it anneals: 70 DEG C of 45s;
D. extend: 72 DEG C of 90s;
E.b-d reacts 30 circulations;
F. extend: 72 DEG C of 10min.
(Beijing Hua Da bio-engineering corporation) is sequenced in finally obtained PCR product, the results showed that, amplification obtains at this time
The phospholipase D segment plDm209-519 of the bis- mutation of Asn209Ile and Asp519Val, sequence are as shown in table 1.
It is consistent with embodiment 2 or/and 3 step of embodiment to continue other each mutagenesis steps, all mutant primers
Sequence see the table below, and above-mentioned steps are pressed on the basis of plDm209-519, and only according to the form below replaces primer, successively carry out
The point mutation of Asp139Ile, Asp256Thr, Gln388Cys, and give to sequencing company and be sequenced, it is prominent that confirmation obtains 5 amino acid
The phospholipase D segment plDm139-209-256-388-519 of height, amino acid sequence is as shown in SEQ ID NO.4, nucleosides
Acid sequence is as shown in SEQ ID NO.3.
Mutant | The end F primer | The end R primer |
plDm139 | P7:SEQ ID NO.11 | P8:SEQ ID NO.12 |
plDm209 | P3:SEQ ID NO.7 | P4:SEQ ID NO.8 |
plDm256 | P9:SEQ ID NO.13 | P10:SEQ ID NO.14 |
plDm388 | P11:SEQ ID NO.15 | P12:SEQ ID NO.16 |
plDm519 | P5:SEQ ID NO.9 | P6:SEQ ID NO.10 |
Embodiment 4: the building of the high vigor phospholipase D recombinant bacterium of bacillus subtilis
1. the building of expression vector pBSA43
Using bacillus coli-bacillus subtilis shuttle cloning vector pBE2 as skeleton, it is cloned into a strong bacillus
Constitutive promoter P43 and the levansucrase signal sequence sacB that recombinant protein can be made directly to be secreted into culture medium are obtained
Obtained expression vector pBSA43.It has AmprAnd KmrGene, can in Escherichia coli using amicillin resistance as
Selection markers, while again can be in bacillus subtilis, bacillus licheniformis using kalamycin resistance as selection markers.
2. constructing high vigor phospholipase D expression vector pBSA43-plDmx
By the high vigor phospholipase D of over-lap PCR building and bacillus subtilis expression vector pBSA43 all through BamHI
It with HindIII double digestion, is then attached, building obtains recombinant plasmid pBSA43-plDmx, conversion to bacillus coli DH 5 alpha
Competent cell selects positive transformant, extracts plasmid and carries out digestion verification and be sequenced, determination constructs successfully, that is, is recombinated
Bacterial strain pBSA43-plDmx.
3. expression vector pBSA43-plDmx converts bacillus subtilis WB600
It is added in 60 μ L competent cells and 1 μ L (50ng/ μ L) pBSA43-plDmx, mixes into the 1mm electricity revolving cup of pre-cooling
Even and ice bath 5min is arranged parameter (25 μ F, 200 Ω, 4.5-5.0ms), and electric shock is primary, and 1mL recovery culture is immediately added
Base (LB+0.5mol/L sorbierite+0.5mol/L mannitol) draws 37 DEG C of shaking table shake cultures into 1.5mlEP pipe after mixing
3h leaves and takes 200 μ L recovery objects and is coated on resistant LB plate after centrifugation, 37 DEG C are cultivated for 24 hours, picking transformant, upgrading
Grain, digestion verification (as shown in Figure 2), obtain bacillus subtilis recombinant bacterial strain WB600/pBSA43-plDmx.
Embodiment 5: the free expression recombinant bacterium of the building high vigor phospholipase D of Pichia pastoris
1. the building of high vigor phospholipase D Expression vector pPIC9K-plDmx
Over-lap PCR purified product and yeast expression vector pPIC 9K are passed through into EcoRI and NotI double digestion, then
It is attached, converts into bacillus coli DH 5 alpha competent cell, select AmprPositive transformant, upgrading after bacterium colony culture
Grain, digestion verification succeed (as shown in Figure 3) to get recombinant expression carrier pPIC 9K-plDmx is arrived.
2. constructing high vigor phospholipase D height expresses recombinant bacterial strain
(1) linearisation of Plasmid DNA
Before converting Pichia pastoris, respectively with SacI and SalI restriction enzyme to recombinant expression plasmid pPIC 9K-
PlDmx carries out linearized enzyme digestion.
(2) linearization plasmid pPIC 9K-plDmx electricity goes to Pichia pastoris
1. competent cell and linearization plasmid pPIC 9K-plDmx are added in the centrifuge tube of 1.5mL pre-cooling, piping and druming
It mixes, is then added in the electric revolving cup of pre-cooling;
2. to conversion cup ice bath 10min, subsequent electrotransformation;
3. after electric shock, the sorbitol solution of the 1mol/L of 1mL pre-cooling is added immediately in electric revolving cup, and electricity is turned liquid transfer
Into new 1.5mL centrifuge tube;
4. 30 DEG C of stationary culture 1-2h, absorption Pichia pastoris GS115 electricity turns 200 μ L of liquid and is coated on MD culture medium.
(3) identification of positive transformant and the screening of phospholipase D superior strain
1. being coated with electricity turns the MD plate of liquid in 30 DEG C of culture 2-3d;
2. picking transformant extracts Yeast genome, carries out PCR as template after 100 times of dilution.Separately to be transferred to empty plasmid
The Pichia pastoris GS115 of pPIC 9K/pPIC 9K determines positive transformant as control.
3. first picking single colonie on the plate of geneticin resistant containing various concentration is bigger after determining positive transformant
High geneticin resistant transformant then measures the phospholipase D enzyme activity for the transformant picked out, to obtain phospholipase D respectively
Superior strain GS115/pPIC 9K-plDmx.
Embodiment 6: the building of the high vigor phospholipase D recombinant bacterium of Pichia pastoris surface display
1. the building of recombinant plasmid pPIC9K-Flo-plDmx
By over-lap PCR purified product and Pichia pastoris surface display expression vector pPIC 9K-Flo by SnaBI and
EcoRI double digestion, is then attached, and converts into bacillus coli DH 5 alpha competence, selects AmprPositive transformant, bacterium colony
Upgrading grain after culture, digestion verification succeed (as shown in Figure 4) to get recombinant expression carrier pPIC 9K-Flo-plDmx is arrived.
2. the building of Pichia pastoris recombinant bacterium
By the correct recombinant expression carrier pPIC 9K-Flo-plDmx of sequence verification after SalI is linearized, electrotransformation is used
Method converts Pichia pastoris GS115, and MD plate screening recon obtains the high vigor phospholipase D weight of Pichia pastoris surface display
Group bacterium GS115/pPIC 9K-Flo-plDmx.
Embodiment 7: expression and preparation of the high vigor phospholipase D in bacillus subtilis recombinant bacterium
1. bacillus subtilis recombinant bacterial strain WB600/pBSA43-plDmx is inoculated in and receives mycin (50 μ g/mL) LB containing card
In fluid nutrient medium, 37 DEG C, 220r/min overnight incubation;
2. 37 DEG C, 220r/min cultivates 48h to get high vigor is arrived by the switching of 1% inoculum concentration in the LB culture medium of 50mL
Phospholipase D crude enzyme liquid;
3. then using salt fractionation method precipitate zymoprotein, collect protein precipitation, after dissolution, dialyse desalination, then through from
After sub- displacement chromatography, gel chromatography, the pure enzyme enzyme powder of high vigor phospholipase D is made in freeze-drying.
Embodiment 8: expression and preparation of the high vigor phospholipase D in the free expression recombinant bacterium of Pichia pastoris
1. the Pichia pastoris recombinant bacterium GS115/pPIC 9K-plDmx on picking YPD plate is seeded to the YPD liquid of 50ml
In culture medium, 30 DEG C, 250r/min culture for 24 hours;
2. being forwarded in BMGY culture medium with 1% inoculum concentration, 30 DEG C, 250r/min is cultivated about for 24 hours, subsequent 4000r/
Min centrifugation 5min obtains thallus, is forwarded to BMMY culture medium;
3. continuing to cultivate, 30 DEG C, 250r/min, every adding 250 μ L methanol for 24 hours.After culture 5 days, it is centrifuged to obtain supernatant,
Obtain the crude enzyme liquid of phospholipase D;
4. then using salt fractionation method precipitate zymoprotein, collect protein precipitation, after dissolution, dialyse desalination, then through from
After sub- displacement chromatography, gel chromatography, the pure enzyme enzyme powder of high vigor phospholipase D is made in freeze-drying.
Embodiment 9: the preparation of the high vigor phospholipase D whole-cell catalyst of Pichia pastoris surface display
1. the high vigor phospholipase D recombinant bacterium GS115/pPIC of Pichia pastoris surface display on picking YPD plate
9K-Flo-plDmx is seeded in the YPD fluid nutrient medium of 50ml, 30 DEG C, 250r/min culture for 24 hours;
2. being transferred in fresh BMGY culture medium with 1% inoculum concentration, 30 DEG C, 250r/min is cultivated about for 24 hours, then
4000r/min centrifugation 5min obtains thallus, is forwarded to BMMY culture medium;
3. continuing to cultivate, 30 DEG C, 250r/min, every adding 250 μ L methanol for 24 hours.After culture 5 days, it is collected by centrifugation and takes
Thallus, used film water rinse 1-2 times, and Pichia pastoris surface display height is made through vacuum freeze drying after addition protective agent and lives
Power phospholipase D cell catalyst.
Embodiment 10: phospholipase D vitality test
1. phospholipase D enzyme activity determination principle
Carry out Activity determination using enzyme-linked colorimetric method: phospholipase D catalyzing hydrolysis L- α-lecithin generates choline, and choline is in gallbladder
Generate hydrogen peroxide under the action of alkali oxidizing ferment, hydrogen peroxide under the action of peroxidase with 4- amino antipyrine and phenol
Quinone imines substance that show color is generated, has light absorption value under 500nm wavelength.
2. phospholipase D enzyme activity determination method
(1) lecithin emulsions: 0.345g lecithin, 2ml ether, 3ml7.5%TritanX-100,20mlH2O, it is sufficiently mixed
It is even.
(2) reaction terminating liquid: 1M Tris-HCl, 0.5M EDTA, pH8.0
The determination step of phospholipase D:
1.15ml lecithin emulsions, 0.1ml 100mM Tris-HCl, 0.05ml CaCl are added in 10ml test tube2,
0.1ml crude enzyme liquid, 37 DEG C of water-bath 10min are then added 0.2ml reaction terminating liquid, boil 5min, be cooled to room temperature.Then
It is added containing 2U containing choline oxidase, 4U peroxidase, 2mg 4- antipyrine, 1mg phenol, 20mg Tritan X-100
4ml 10mM Tris-HCl, 37 DEG C of reaction 20min then survey light absorption value at 500nm.
Blank sample is returned to zero with the enzyme solution in water substitution reaction with this.
Enzyme activity definition: when pH=8.0, T=37 DEG C, catalyzing hydrolysis L- α-lecithin discharges 1.0 μ in phospholipase D 1min
Enzyme amount required for the choline of mol.
The enzyme activity of phospholipase D enzyme activity determination, the high vigor phospholipase D that measurement fermentation obtains is listed as follows:
Embodiment 11: phosphatidic acid is prepared with high vigor phospholipase D
Substrate is 1g soybean lecithin (PC content 90%), is dissolved in the phosphate buffer of 10ml pH7.0, by every milliliter
Reaction system 3U high vigor phospholipase D is added, wherein high vigor phospholipase D is that prepare (can be by any by 7-9 of the embodiment of the present invention
Mutant ferments to obtain, and enzyme powder additive amount reaches 3U/ml when catalysis).40 DEG C of reaction temperature, make in magnetic stirrer
With lower reaction 12h, phosphatidic acid is then obtained by 30ml chloroform/methanol (2:1) extraction, the conversion ratio for preparing phosphatidic acid is
72.4%.
Embodiment 12: phosphatidylserine is prepared with high vigor phospholipase D
Substrate is the serine of 1g soybean lecithin (PC content 90%) and 2.5g, is dissolved in the acetic acid-of 5ml pH5.5 respectively
It in sodium acetate buffer, finally mixes, until making total volume 10ml, 6U high vigor phosphatidase is added by every milliliter of reaction system
D, wherein high vigor phospholipase D is that 7-9 of the embodiment of the present invention is prepared and (can be fermented to obtain by any mutant, enzyme powder adds when catalysis
Dosage reaches 6U/ml).40 DEG C of reaction temperature, 12h is reacted under magnetic stirrer effect, then passes through 30ml chlorine
Imitative/methanol (2:1) extraction obtains phosphatidyl serine, and the conversion ratio for preparing phosphatidylserine is 78.5%.
Sequence table
<110>University Of Science and Technology Of Tianjin
<120>phospholipase D and its application
<130> 1
<141> 2019-06-18
<160> 16
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1683
<212> DNA
<213>Hao Shi streptomycete (Streptomyces halstediiTCCC 21102)
<400> 1
atgatcaagg ttggtggtgt tgctgaccca agatctagac cagaaccacc accatctcag 60
ggtactactt tggctagaac tgttagaact actgctttgg tttccacttc cgctttggct 120
ttgggtttct ctttgttggg tgctactgct actgttccag cttacgctgc tgaagctcca 180
actccacatt tggactctgt tgagcagact ttgagacagg tttctccagg tttggaaggt 240
tccgtttggg aaagaactgc tggtaacaga ttgggttctt ccactccagg tggtgctgat 300
tggttgttgc aaactccagg ttgttggggt gatgctgctt gtactgatag accaggttct 360
agaagattgt tggacaagat gagacaggac attgctggtg ctagacagac tgttgacatc 420
tccactttgg ctccatttcc aaacggtggt taccaggatg ctatcgttgc tggtttgaaa 480
gagtccgctc agaagggaaa cagattgaag gttagaatca tggttggtgc tgctccaatc 540
taccactcta ctgttattcc atcctcctac agagatgagt tgttggctaa gttgggtcca 600
gctgctgctg ctaacatcac tttgaacgtt gcttccatga ctacttccaa gacttccttc 660
tcttggaacc actccaagtt gatcgttgtt gacggtggtt ccgttatcac tggtggtatc 720
aactcttgga aggacgacta cttggacact actcacccag tttctgacgt tgacttggct 780
ttgtctggtc ctgctgctgg ttctgctggt agatacttgg attctttgtg ggactggact 840
tgtagaaaca agggtaactg gtcctccgtt tggttcgctg cttcttctgg tgctgactgt 900
atgccagctt tgccaagacc agctactcct gaaggtggtg gtgatgttcc tgctttggct 960
gttggtggtt tgggtgttgg tattagacag aacgacccta cttcctcatt cagaccagtt 1020
ttgcctactg ctggtgacac taagtgtggt attggtgttt ccgacaagac taacgctgac 1080
agagactacg acactgttaa cccagaagaa tccgctttga gagctttggt ttcttccgct 1140
acttcccaca ttgagatttc ccaacaagac gttcacgcta cttgtccacc attgccaaga 1200
tacgaggtta gattgtacga cgctttggct gctaagttgg tttccggtgt taaggttaga 1260
atcgttgttt ccgacccagc taacagaggt actattggat ctggtggtta ctcccagatc 1320
aagtccttgt ctgaagtttc cgatgctttg agaggtagag ttactgcttt gactggtgac 1380
ggtggtagag ctagaactgc tttgtgtgag aacttgcagt tggctacttt cagagcttct 1440
gacaagccaa cttgggctga tggtaagcca tacgctcaac accacaaatt ggtttctgtt 1500
gacggatccg ctttctacat cggatccaag aacttgtacc catcctggtt gcaagacttc 1560
ggttacgttg ttgaatctcc tgccgctgct gctcagttga gaactgattt gttggatcct 1620
cagtggagat actcccaggc tacagctact tacgattacg ctagaggttt gtgtcagggt 1680
taa 1683
<210> 2
<211> 560
<212> PRT
<213>Hao Shi streptomycete (Streptomyces halstediiTCCC 21102)
<400> 2
Met Ile Lys Val Gly Gly Val Ala Asp Pro Arg Ser Arg Pro Glu Pro
1 5 10 15
Pro Pro Ser Gln Gly Thr Thr Leu Ala Arg Thr Val Arg Thr Thr Ala
20 25 30
Leu Val Ser Thr Ser Ala Leu Ala Leu Gly Phe Ser Leu Leu Gly Ala
35 40 45
Thr Ala Thr Val Pro Ala Tyr Ala Ala Glu Ala Pro Thr Pro His Leu
50 55 60
Asp Ser Val Glu Gln Thr Leu Arg Gln Val Ser Pro Gly Leu Glu Gly
65 70 75 80
Ser Val Trp Glu Arg Thr Ala Gly Asn Arg Leu Gly Ser Ser Thr Pro
85 90 95
Gly Gly Ala Asp Trp Leu Leu Gln Thr Pro Gly Cys Trp Gly Asp Ala
100 105 110
Ala Cys Thr Asp Arg Pro Gly Ser Arg Arg Leu Leu Asp Lys Met Arg
115 120 125
Gln Asp Ile Ala Gly Ala Arg Gln Thr Val Asp Ile Ser Thr Leu Ala
130 135 140
Pro Phe Pro Asn Gly Gly Tyr Gln Asp Ala Ile Val Ala Gly Leu Lys
145 150 155 160
Glu Ser Ala Gln Lys Gly Asn Arg Leu Lys Val Arg Ile Met Val Gly
165 170 175
Ala Ala Pro Ile Tyr His Ser Thr Val Ile Pro Ser Ser Tyr Arg Asp
180 185 190
Glu Leu Leu Ala Lys Leu Gly Pro Ala Ala Ala Ala Asn Ile Thr Leu
195 200 205
Asn Val Ala Ser Met Thr Thr Ser Lys Thr Ser Phe Ser Trp Asn His
210 215 220
Ser Lys Leu Ile Val Val Asp Gly Gly Ser Val Ile Thr Gly Gly Ile
225 230 235 240
Asn Ser Trp Lys Asp Asp Tyr Leu Asp Thr Thr His Pro Val Ser Asp
245 250 255
Val Asp Leu Ala Leu Ser Gly Pro Ala Ala Gly Ser Ala Gly Arg Tyr
260 265 270
Leu Asp Ser Leu Trp Asp Trp Thr Cys Arg Asn Lys Gly Asn Trp Ser
275 280 285
Ser Val Trp Phe Ala Ala Ser Ser Gly Ala Asp Cys Met Pro Ala Leu
290 295 300
Pro Arg Pro Ala Thr Pro Glu Gly Gly Gly Asp Val Pro Ala Leu Ala
305 310 315 320
Val Gly Gly Leu Gly Val Gly Ile Arg Gln Asn Asp Pro Thr Ser Ser
325 330 335
Phe Arg Pro Val Leu Pro Thr Ala Gly Asp Thr Lys Cys Gly Ile Gly
340 345 350
Val Ser Asp Lys Thr Asn Ala Asp Arg Asp Tyr Asp Thr Val Asn Pro
355 360 365
Glu Glu Ser Ala Leu Arg Ala Leu Val Ser Ser Ala Thr Ser His Ile
370 375 380
Glu Ile Ser Gln Gln Asp Val His Ala Thr Cys Pro Pro Leu Pro Arg
385 390 395 400
Tyr Glu Val Arg Leu Tyr Asp Ala Leu Ala Ala Lys Leu Val Ser Gly
405 410 415
Val Lys Val Arg Ile Val Val Ser Asp Pro Ala Asn Arg Gly Thr Ile
420 425 430
Gly Ser Gly Gly Tyr Ser Gln Ile Lys Ser Leu Ser Glu Val Ser Asp
435 440 445
Ala Leu Arg Gly Arg Val Thr Ala Leu Thr Gly Asp Gly Gly Arg Ala
450 455 460
Arg Thr Ala Leu Cys Glu Asn Leu Gln Leu Ala Thr Phe Arg Ala Ser
465 470 475 480
Asp Lys Pro Thr Trp Ala Asp Gly Lys Pro Tyr Ala Gln His His Lys
485 490 495
Leu Val Ser Val Asp Gly Ser Ala Phe Tyr Ile Gly Ser Lys Asn Leu
500 505 510
Tyr Pro Ser Trp Leu Gln Asp Phe Gly Tyr Val Val Glu Ser Pro Ala
515 520 525
Ala Ala Ala Gln Leu Arg Thr Asp Leu Leu Asp Pro Gln Trp Arg Tyr
530 535 540
Ser Gln Ala Thr Ala Thr Tyr Asp Tyr Ala Arg Gly Leu Cys Gln Gly
545 550 555 560
<210> 3
<211> 1683
<212> DNA
<213>artificial sequence ()
<400> 3
atgatcaagg ttggtggtgt tgctgaccca agatctagac cagaaccacc accatctcag 60
ggtactactt tggctagaac tgttagaact actgctttgg tttccacttc cgctttggct 120
ttgggtttct ctttgttggg tgctactgct actgttccag cttacgctgc tgaagctcca 180
actccacatt tggactctgt tgagcagact ttgagacagg tttctccagg tttggaaggt 240
tccgtttggg aaagaactgc tggtaacaga ttgggttctt ccactccagg tggtgctgat 300
tggttgttgc aaactccagg ttgttggggt gatgctgctt gtactgatag accaggttct 360
agaagattgt tggacaagat gagacaggac attgctggtg ctagacagac tgttatcatc 420
tccactttgg ctccatttcc aaacggtggt taccaggatg ctatcgttgc tggtttgaaa 480
gagtccgctc agaagggaaa cagattgaag gttagaatca tggttggtgc tgctccaatc 540
taccactcta ctgttattcc atcctcctac agagatgagt tgttggctaa gttgggtcca 600
gctgctgctg ctaacatcac tttgatcgtt gcttccatga ctacttccaa gacttccttc 660
tcttggaacc actccaagtt gatcgttgtt gacggtggtt ccgttatcac tggtggtatc 720
aactcttgga aggacgacta cttggacact actcacccag tttctaccgt tgacttggct 780
ttgtctggtc ctgctgctgg ttctgctggt agatacttgg attctttgtg ggactggact 840
tgtagaaaca agggtaactg gtcctccgtt tggttcgctg cttcttctgg tgctgactgt 900
atgccagctt tgccaagacc agctactcct gaaggtggtg gtgatgttcc tgctttggct 960
gttggtggtt tgggtgttgg tattagacag aacgacccta cttcctcatt cagaccagtt 1020
ttgcctactg ctggtgacac taagtgtggt attggtgttt ccgacaagac taacgctgac 1080
agagactacg acactgttaa cccagaagaa tccgctttga gagctttggt ttcttccgct 1140
acttcccaca ttgagatttc ctgccaagac gttcacgcta cttgtccacc attgccaaga 1200
tacgaggtta gattgtacga cgctttggct gctaagttgg tttccggtgt taaggttaga 1260
atcgttgttt ccgacccagc taacagaggt actattggat ctggtggtta ctcccagatc 1320
aagtccttgt ctgaagtttc cgatgctttg agaggtagag ttactgcttt gactggtgac 1380
ggtggtagag ctagaactgc tttgtgtgag aacttgcagt tggctacttt cagagcttct 1440
gacaagccaa cttgggctga tggtaagcca tacgctcaac accacaaatt ggtttctgtt 1500
gacggatccg ctttctacat cggatccaag aacttgtacc catcctggtt gcaagtcttc 1560
ggttacgttg ttgaatctcc tgccgctgct gctcagttga gaactgattt gttggatcct 1620
cagtggagat actcccaggc tacagctact tacgattacg ctagaggttt gtgtcagggt 1680
taa 1683
<210> 4
<211> 560
<212> PRT
<213>artificial sequence ()
<400> 4
Met Ile Lys Val Gly Gly Val Ala Asp Pro Arg Ser Arg Pro Glu Pro
1 5 10 15
Pro Pro Ser Gln Gly Thr Thr Leu Ala Arg Thr Val Arg Thr Thr Ala
20 25 30
Leu Val Ser Thr Ser Ala Leu Ala Leu Gly Phe Ser Leu Leu Gly Ala
35 40 45
Thr Ala Thr Val Pro Ala Tyr Ala Ala Glu Ala Pro Thr Pro His Leu
50 55 60
Asp Ser Val Glu Gln Thr Leu Arg Gln Val Ser Pro Gly Leu Glu Gly
65 70 75 80
Ser Val Trp Glu Arg Thr Ala Gly Asn Arg Leu Gly Ser Ser Thr Pro
85 90 95
Gly Gly Ala Asp Trp Leu Leu Gln Thr Pro Gly Cys Trp Gly Asp Ala
100 105 110
Ala Cys Thr Asp Arg Pro Gly Ser Arg Arg Leu Leu Asp Lys Met Arg
115 120 125
Gln Ile Ile Ala Gly Ala Arg Gln Thr Val Ile Ile Ser Thr Leu Ala
130 135 140
Pro Phe Pro Asn Gly Gly Tyr Gln Asp Ala Ile Val Ala Gly Leu Lys
145 150 155 160
Glu Ser Ala Gln Lys Gly Asn Arg Leu Lys Val Arg Ile Met Val Gly
165 170 175
Ala Ala Pro Ile Tyr His Ser Thr Val Ile Pro Ser Ser Tyr Arg Asp
180 185 190
Glu Leu Leu Ala Lys Leu Gly Pro Ala Ala Ala Ala Asn Ile Thr Leu
195 200 205
Ile Val Ala Ser Met Thr Thr Ser Lys Thr Ser Phe Ser Trp Asn His
210 215 220
Ser Lys Leu Ile Val Val Asp Gly Gly Ser Val Ile Thr Gly Gly Ile
225 230 235 240
Asn Ser Trp Lys Asp Asp Tyr Leu Asp Thr Thr His Pro Val Ser Thr
245 250 255
Val Asp Leu Ala Leu Ser Gly Pro Ala Ala Gly Ser Ala Gly Arg Tyr
260 265 270
Leu Asp Ser Leu Trp Asp Trp Thr Cys Arg Asn Lys Gly Asn Trp Ser
275 280 285
Ser Val Trp Phe Ala Ala Ser Ser Gly Ala Asp Cys Met Pro Ala Leu
290 295 300
Pro Arg Pro Ala Thr Pro Glu Gly Gly Gly Asp Val Pro Ala Leu Ala
305 310 315 320
Val Gly Gly Leu Gly Val Gly Ile Arg Gln Asn Asp Pro Thr Ser Ser
325 330 335
Phe Arg Pro Val Leu Pro Thr Ala Gly Asp Thr Lys Cys Gly Ile Gly
340 345 350
Val Ser Asp Lys Thr Asn Ala Asp Arg Asp Tyr Asp Thr Val Asn Pro
355 360 365
Glu Glu Ser Ala Leu Arg Ala Leu Val Ser Ser Ala Thr Ser His Ile
370 375 380
Glu Ile Ser Cys Gln Asp Val His Ala Thr Cys Pro Pro Leu Pro Arg
385 390 395 400
Tyr Glu Val Arg Leu Tyr Asp Ala Leu Ala Ala Lys Leu Val Ser Gly
405 410 415
Val Lys Val Arg Ile Val Val Ser Asp Pro Ala Asn Arg Gly Thr Ile
420 425 430
Gly Ser Gly Gly Tyr Ser Gln Ile Lys Ser Leu Ser Glu Val Ser Asp
435 440 445
Ala Leu Arg Gly Arg Val Thr Ala Leu Thr Gly Asp Gly Gly Arg Ala
450 455 460
Arg Thr Ala Leu Cys Glu Asn Leu Gln Leu Ala Thr Phe Arg Ala Ser
465 470 475 480
Asp Lys Pro Thr Trp Ala Asp Gly Lys Pro Tyr Ala Gln His His Lys
485 490 495
Leu Val Ser Val Asp Gly Ser Ala Phe Tyr Ile Gly Ser Lys Asn Leu
500 505 510
Tyr Pro Ser Trp Leu Gln Val Phe Gly Tyr Val Val Glu Ser Pro Ala
515 520 525
Ala Ala Ala Gln Leu Arg Thr Asp Leu Leu Asp Pro Gln Trp Arg Tyr
530 535 540
Ser Gln Ala Thr Ala Thr Tyr Asp Tyr Ala Arg Gly Leu Cys Gln Gly
545 550 555 560
<210> 5
<211> 25
<212> DNA
<213>artificial sequence ()
<400> 5
atgatcaagg ttggtggtgt tgctg 25
<210> 6
<211> 32
<212> DNA
<213>artificial sequence ()
<400> 6
ttaaccctga cacaaacctc tagcgtaatc gt 32
<210> 7
<211> 36
<212> DNA
<213>artificial sequence ()
<400> 7
atggaagcaa cgatcaaagt gatgttagca gcagca 36
<210> 8
<211> 36
<212> DNA
<213>artificial sequence ()
<400> 8
tgctgctgct aacatcactt tgatcgttgc ttccat 36
<210> 9
<211> 35
<212> DNA
<213>artificial sequence ()
<400> 9
caacaacgta accgaagact tgcaaccagg atggg 35
<210> 10
<211> 35
<212> DNA
<213>artificial sequence ()
<400> 10
cccatcctgg ttgcaagtct tcggttacgt tgttg 35
<210> 11
<211> 38
<212> DNA
<213>artificial sequence ()
<400> 11
ggtgctagac agactgttat catctccact ttggctcc 38
<210> 12
<211> 38
<212> DNA
<213>artificial sequence ()
<400> 12
ggagccaaag tggagatgat aacagtctgt ctagcacc 38
<210> 13
<211> 40
<212> DNA
<213>artificial sequence ()
<400> 13
cttggacact actcacccag tttctaccgt tgacttggct 40
<210> 14
<211> 40
<212> DNA
<213>artificial sequence ()
<400> 14
agccaagtca acggtagaaa ctgggtgagt agtgtccaag 40
<210> 15
<211> 47
<212> DNA
<213>artificial sequence ()
<400> 15
tacttcccac attgagattt cctgccaaga cgttcacgct acttgtc 47
<210> 16
<211> 47
<212> DNA
<213>artificial sequence ()
<400> 16
gacaagtagc gtgaacgtct tggcaggaaa tctcaatgtg ggaagta 47
Claims (6)
1. a kind of phospholipase D mutant, which is characterized in that based on phospholipase D amino acid sequence shown in SEQ ID No.2, hair
Raw following mutation: Asp139Ile;Or Asp139Ile, Asn209Ile;Or Asp139Ile, Asp256Thr;Or Asp139Ile,
Gln388Cys;Or Asp139Ile, Asp519Val;Or Asp139Ile, Asn209Ile, Asp256Thr;Or Asp139Ile,
Asn209Ile, Gln388Cys;Or Asp139Ile, Asn209Ile, Asp519Val;Or Asp139Ile, Asp256Thr,
Gln388Cys;Or Asp139Ile, Asp256Thr, Asp519Val;Or Asp139Ile, Gln388Cys, Asp519Val;Or
Asp139Ile, Asn209Ile, Asp256Thr, Gln388Cys;Or Asp139Ile, Asn209Ile, Asp256Thr,
Asp519Val;Or Asp139Ile, Asp256Thr, Gln388Cys, Asp519Val;Or Asp139Ile, Asn209Ile,
Gln388Cys, Asp519Val.
2. the encoding gene of phospholipase D mutant described in claim 1.
3. the purposes of phospholipase D mutant or gene as claimed in claim 2 described in claim 1, which is characterized in that be used for phosphorus
The preparation of resin acid and phosphatidylserine.
4. a kind of expression vector or host cell comprising gene as claimed in claim 2.
5. carrier as claimed in claim 4 or host cell, which is characterized in that the carrier is pBSA43, and host cell is
Bacillus subtilis WB600;Alternatively, the carrier is pPIC 9K, host cell is Pichia pastoris GS115;Alternatively, carrier is
PPIC9K-Flo, host cell are Pichia pastoris GS115.
6. the preparation method of phospholipase D mutant described in claim 1, which is characterized in that steps are as follows:
(1) gene as claimed in claim 2 is subjected to digestion, connect to have obtained new recombinant vector with carrier;
(2) recombinant vector is transformed into host cell, obtains recombinant bacterial strain, recombinant bacterial strain ferments later, obtain high vigor
Phospholipase D.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910528115.0A CN110129299B (en) | 2016-06-02 | 2016-06-02 | Phospholipase D and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910528115.0A CN110129299B (en) | 2016-06-02 | 2016-06-02 | Phospholipase D and application thereof |
CN201610402557.7A CN106085984B (en) | 2016-06-02 | 2016-06-02 | A kind of novel phospholipase D and its method for preparing phosphatidic acid, phosphatidylserine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610402557.7A Division CN106085984B (en) | 2016-06-02 | 2016-06-02 | A kind of novel phospholipase D and its method for preparing phosphatidic acid, phosphatidylserine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110129299A true CN110129299A (en) | 2019-08-16 |
CN110129299B CN110129299B (en) | 2021-08-03 |
Family
ID=57227467
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910528115.0A Active CN110129299B (en) | 2016-06-02 | 2016-06-02 | Phospholipase D and application thereof |
CN201910528114.6A Active CN110129298B (en) | 2016-06-02 | 2016-06-02 | Phospholipase D mutant and application thereof |
CN201610402557.7A Active CN106085984B (en) | 2016-06-02 | 2016-06-02 | A kind of novel phospholipase D and its method for preparing phosphatidic acid, phosphatidylserine |
CN201910528146.6A Active CN110283803B (en) | 2016-06-02 | 2016-06-02 | Phospholipase D and method for preparing phosphatidic acid and phosphatidylserine by using phospholipase D |
CN201910527208.1A Active CN110218712B (en) | 2016-06-02 | 2016-06-02 | Phospholipase D mutant and application thereof in preparation of phosphatidic acid and phosphatidylserine |
CN201910528141.3A Active CN110129300B (en) | 2016-06-02 | 2016-06-02 | Phospholipase D |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910528114.6A Active CN110129298B (en) | 2016-06-02 | 2016-06-02 | Phospholipase D mutant and application thereof |
CN201610402557.7A Active CN106085984B (en) | 2016-06-02 | 2016-06-02 | A kind of novel phospholipase D and its method for preparing phosphatidic acid, phosphatidylserine |
CN201910528146.6A Active CN110283803B (en) | 2016-06-02 | 2016-06-02 | Phospholipase D and method for preparing phosphatidic acid and phosphatidylserine by using phospholipase D |
CN201910527208.1A Active CN110218712B (en) | 2016-06-02 | 2016-06-02 | Phospholipase D mutant and application thereof in preparation of phosphatidic acid and phosphatidylserine |
CN201910528141.3A Active CN110129300B (en) | 2016-06-02 | 2016-06-02 | Phospholipase D |
Country Status (1)
Country | Link |
---|---|
CN (6) | CN110129299B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110218712A (en) * | 2016-06-02 | 2019-09-10 | 天津科技大学 | Phospholipase D mutant and its prepare phosphatidic acid, the application in phosphatidylserine |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106957850B (en) * | 2017-05-12 | 2020-06-12 | 南京工业大学 | Genetically engineered bacterium for producing phospholipase D and construction method and application thereof |
CN107312756A (en) * | 2017-07-10 | 2017-11-03 | 江苏诚信药业有限公司 | It is a kind of to catalyze and synthesize biology enzyme of phosphatidylserine and its preparation method and application |
CN107365755A (en) * | 2017-09-01 | 2017-11-21 | 天津科技大学 | A kind of novel lipase and its gene, engineering bacteria and preparation method |
CN107384893A (en) * | 2017-09-01 | 2017-11-24 | 天津科技大学 | A kind of thermostable lipase and its preparation and application |
CN107586764B (en) * | 2017-09-26 | 2020-06-09 | 天津科技大学 | Glutamine transaminase mutant, gene, engineering bacteria and preparation method thereof |
CN109957520B (en) * | 2017-12-25 | 2022-12-09 | 丰益(上海)生物技术研发中心有限公司 | Pichia pastoris strain for exogenous gene expression |
CN108159421B (en) * | 2018-02-05 | 2021-05-18 | 苏州大学 | Application of phosphatidylserine blocking agent in preparation of medicine for treating diseases related to platelet quantity reduction |
CN108103115B (en) * | 2018-03-02 | 2021-07-06 | 江苏中酶生物科技有限公司 | Method for preparing phosphatidic acid by micro-aqueous phase |
CN108795837B (en) * | 2018-07-06 | 2021-01-29 | 江南大学 | Bacillus subtilis engineering bacterium for efficiently expressing phospholipase D |
CN108841770A (en) * | 2018-07-06 | 2018-11-20 | 江南大学 | A kind of bacillus subtilis engineering bacteria that can express phospholipase D |
WO2020133314A1 (en) * | 2018-12-29 | 2020-07-02 | 邦泰生物工程(深圳)有限公司 | Phospholipase d mutant, use thereof and method for preparing phosphatidylserine by means of same |
CN110004124A (en) * | 2019-02-28 | 2019-07-12 | 江南大学 | A kind of encoding gene of phospholipase D and its expression and application |
CN114891765B (en) * | 2019-11-21 | 2023-12-19 | 天津科技大学 | Phospholipase and application thereof |
CN111363733B (en) * | 2020-03-10 | 2022-04-08 | 天津科技大学 | Heat-resistant phospholipase D mutant and preparation method thereof and method for synthesizing functional phospholipid |
CN112662645B (en) * | 2021-01-19 | 2022-04-22 | 华南理工大学 | Sphingomyelinase D mutant and application thereof |
CN112899256B (en) * | 2021-01-29 | 2023-03-21 | 华南理工大学 | Low-temperature-resistant phospholipase D from Antarctic bacteria and preparation method and application thereof |
CN113801862B (en) * | 2021-08-20 | 2023-06-20 | 华南理工大学 | Marine streptomycete phospholipase D mutant and preparation method of recombinant expression strain thereof |
CN116790553B (en) * | 2023-08-25 | 2023-11-10 | 中国海洋大学 | Phospholipase D-PKV-S109L and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1659276A (en) * | 2002-04-19 | 2005-08-24 | 戴弗萨公司 | Phospholipases, nucleic acids encoding them and methods of making and using them |
CN1897919A (en) * | 2003-09-25 | 2007-01-17 | 酶学技术有限公司 | Stabilized formulations of phosphatidylserine |
US7993874B2 (en) * | 2006-03-10 | 2011-08-09 | Mitsubishi-Kagaku Foods Corporation | Phospholipase C enzyme(s) |
WO2012076435A1 (en) * | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 |
CN105200027A (en) * | 2005-10-12 | 2015-12-30 | 金克克国际有限公司 | Use and production of storage-stable neutral metalloprotease |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR016969A1 (en) * | 1997-10-23 | 2001-08-01 | Procter & Gamble | PROTEASE VARIANTE, ADN, EXPRESSION VECTOR, GUEST MICROORGANISM, CLEANING COMPOSITION, ANIMAL FOOD AND COMPOSITION TO TREAT A TEXTILE |
WO2000018890A2 (en) * | 1998-09-30 | 2000-04-06 | Millennium Pharmaceuticals, Inc. | Protein phosphatase molecules and uses therefor |
RU2235775C2 (en) * | 1998-11-27 | 2004-09-10 | Новозимс А/С | Method for preparing lipolytic enzyme variant and lipolytic enzyme (variants) |
CA2467415C (en) * | 2002-01-16 | 2014-03-11 | Novozymes A/S | Lipolytic enzyme variants and method for their production |
US7226771B2 (en) * | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
ES2346654T3 (en) * | 2003-06-19 | 2010-10-19 | Novozymes A/S | PROTEASES |
CN101379187A (en) * | 2006-02-02 | 2009-03-04 | 国立大学法人名古屋大学 | Novel phospholipase D |
PT2057274E (en) * | 2006-09-21 | 2014-03-13 | Dsm Ip Assets Bv | Phospholipases, nucleic acids encoding them and methods for making and using them |
BRPI0922084B1 (en) * | 2008-11-11 | 2020-12-29 | Danisco Us Inc. | subtilisin variant isolated from a bacillus subtilisin and its cleaning composition |
WO2011010485A1 (en) * | 2009-07-22 | 2011-01-27 | 石川県 | Process for production of eicosanoid, eicosanoid biosynthesis gene derived from marchantia polymorpha, and use of the gene |
IN2012DN05017A (en) * | 2010-01-14 | 2015-10-02 | Univ Yale | |
CN102906254A (en) * | 2010-03-26 | 2013-01-30 | 诺维信公司 | Thermostable phytase variants |
CN101875929A (en) * | 2010-04-30 | 2010-11-03 | 大连理工大学 | Strain for generating phospholipase D with high and stable yield by utilizing physical and chemical mutation |
BR112013011442A2 (en) * | 2010-11-12 | 2020-08-11 | Novozymes A/S | isolated polypeptide, isolated polynucleotide, nucleic acid construct or expression vector, recombinant host cell, polypeptide production method, composition, use of the polypeptide or composition, methods of reducing the content of phosphorus-containing components in an edible oil, and for degumming of an oil composition |
CN102277394B (en) * | 2011-07-22 | 2013-04-17 | 天津科技大学 | Method for preparing phosphatidylserine in presence of cell-surface display phospholipase D yeast whole cell catalyst |
CN102286440B (en) * | 2011-07-22 | 2012-11-21 | 天津科技大学 | Preparation of high-activity phospholipids enzyme D and cell surface display phospholipids enzyme D yeast whole cell catalysts |
AR087745A1 (en) * | 2011-08-31 | 2014-04-16 | Danisco Us Inc | COMPOSITIONS AND METHODS THAT INCLUDE A VARIANT OF LIPOLITIC ENZYME |
MY188956A (en) * | 2011-12-27 | 2022-01-14 | Commw Scient Ind Res Org | Processes for producing lipids |
US9518980B2 (en) * | 2012-10-10 | 2016-12-13 | Howard Hughes Medical Institute | Genetically encoded calcium indicators |
RU2617842C2 (en) * | 2012-11-08 | 2017-04-28 | Пфайзер Инк. | Heteroaromatic compounds and their application as dopamine d1 ligants |
ES2780398T3 (en) * | 2012-12-10 | 2020-08-25 | Biogen Ma Inc | Anti-blood dendritic cell antigen 2 antibody and use thereof |
CN104017786B (en) * | 2014-06-20 | 2016-06-15 | 天津科技大学 | A kind of phospholipase A2Mutant and preparation method thereof |
CN104004797B (en) * | 2014-06-20 | 2016-03-16 | 天津科技大学 | Sn-2 position is the preparation method of the phosphatidylserine of docosahexenoic acid |
CN110129299B (en) * | 2016-06-02 | 2021-08-03 | 天津科技大学 | Phospholipase D and application thereof |
-
2016
- 2016-06-02 CN CN201910528115.0A patent/CN110129299B/en active Active
- 2016-06-02 CN CN201910528114.6A patent/CN110129298B/en active Active
- 2016-06-02 CN CN201610402557.7A patent/CN106085984B/en active Active
- 2016-06-02 CN CN201910528146.6A patent/CN110283803B/en active Active
- 2016-06-02 CN CN201910527208.1A patent/CN110218712B/en active Active
- 2016-06-02 CN CN201910528141.3A patent/CN110129300B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1659276A (en) * | 2002-04-19 | 2005-08-24 | 戴弗萨公司 | Phospholipases, nucleic acids encoding them and methods of making and using them |
CN1897919A (en) * | 2003-09-25 | 2007-01-17 | 酶学技术有限公司 | Stabilized formulations of phosphatidylserine |
CN105200027A (en) * | 2005-10-12 | 2015-12-30 | 金克克国际有限公司 | Use and production of storage-stable neutral metalloprotease |
US7993874B2 (en) * | 2006-03-10 | 2011-08-09 | Mitsubishi-Kagaku Foods Corporation | Phospholipase C enzyme(s) |
WO2012076435A1 (en) * | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 |
Non-Patent Citations (3)
Title |
---|
CLAUDIO FEDELI等: "On the effects of site-specific mutations on activity and expression of the Streptomyces PMF phospholipase D", 《JOURNAL OF MOLECULAR CATALYSIS》 * |
JASMINA DAMNJANOVI等: "Deletion of a Dynamic Surface Loop Improves Stability and Changes Kinetic Behavior of Phosphatidylinositol-Synthesizing Streptomyces Phospholipase D", 《BIOTECHNOLOGY BIOENGINEERING》 * |
赵紫薇: "色褐链霉菌产磷脂酶D发酵条件优化及诱变育种研究", 《中国优秀硕士学位论文全文数据库》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110218712A (en) * | 2016-06-02 | 2019-09-10 | 天津科技大学 | Phospholipase D mutant and its prepare phosphatidic acid, the application in phosphatidylserine |
CN110283803A (en) * | 2016-06-02 | 2019-09-27 | 天津科技大学 | A kind of novel phospholipase D and its method for preparing phosphatidic acid, phosphatidylserine |
CN110218712B (en) * | 2016-06-02 | 2021-08-03 | 天津科技大学 | Phospholipase D mutant and application thereof in preparation of phosphatidic acid and phosphatidylserine |
CN110283803B (en) * | 2016-06-02 | 2021-08-03 | 天津科技大学 | Phospholipase D and method for preparing phosphatidic acid and phosphatidylserine by using phospholipase D |
Also Published As
Publication number | Publication date |
---|---|
CN110218712A (en) | 2019-09-10 |
CN110218712B (en) | 2021-08-03 |
CN110129300A (en) | 2019-08-16 |
CN110129300B (en) | 2021-08-03 |
CN106085984B (en) | 2019-07-19 |
CN110283803B (en) | 2021-08-03 |
CN110129298A (en) | 2019-08-16 |
CN110129298B (en) | 2021-08-03 |
CN110129299B (en) | 2021-08-03 |
CN110283803A (en) | 2019-09-27 |
CN106085984A (en) | 2016-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106085984B (en) | A kind of novel phospholipase D and its method for preparing phosphatidic acid, phosphatidylserine | |
CN109576244B (en) | Novel lipase, preparation and application thereof | |
CN113201054B (en) | Application of protein FoUPE1 in regulation and control of pathogenicity of banana vascular wilt | |
CN106676081B (en) | A kind of phospholipase B and its application | |
CN114908070B (en) | Phospholipase and method for preparing glycerophospholipids by using phospholipase | |
CN108795837A (en) | A kind of bacillus subtilis engineering bacteria of high efficient expression phospholipase D | |
CN113528362A (en) | Recombinant acid-tolerant yeast with inhibited glycerol production and method for producing lactic acid using the same | |
CN113667682A (en) | YH66-RS11190 gene mutant and application thereof in preparation of L-valine | |
CN106701800B (en) | A kind of Aureobasidium pullulans polyketide synthases gene and its application | |
CN112010953B (en) | Wheat powdery mildew resistance related protein Pm24, and coding gene and application thereof | |
EP1642977B1 (en) | Gene involved in growth-promoting function of acetic acid bacteria and uses thereof | |
CN110468091B (en) | Microorganism and use thereof | |
CN101525580B (en) | Amphiploid histidine auxotroph saccharomyces cerevisiae and constructing method thereof | |
WO2003078635A1 (en) | Gene participating in acetic acid tolerance, acetic acid bacterium bred using the gene, and process for producing vinegar with the use of the acetic acid bacterium | |
CN115073569B (en) | YH 66-09125 gene mutant recombinant bacterium and application thereof in preparation of arginine | |
CN114315998B (en) | CEY17_RS00300 gene mutant and application thereof in preparation of L-valine | |
CN107475269B (en) | acyl-CoA thioesterase gene of candida tropicalis and application thereof | |
WO2008081291A2 (en) | Yeast, recombinant pig lactoferrin, expression vector of recombinant pig lactoferring gene, recombinant pig lactoferrin and production processes thereof. | |
JP2005013113A (en) | Gene involved in acetic acid tolerance, acetic acid bacteria bred using the gene, and method for producing vinegar using the acetic acid bacteria | |
JP2005046071A (en) | Gene involved in acetic acid tolerance | |
JP2005040098A (en) | Gene participating in acetic acid tolerance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |